Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Amdizalisib [inn]
2. F3ymy7783p
3. 1894229-03-8
4. 4-amino-6-[[(1s)-1-(3-chloro-6-phenylimidazo[1,2-b]pyridazin-7-yl)ethyl]amino]pyrimidine-5-carbonitrile
5. 4-amino-6-{[(1s)-1-(3-chloro-6-phenylimidazo[1,2-b]pyridazin-7-yl)ethyl]amino}pyrimidine-5-carbonitrile
6. 5-pyrimidinecarbonitrile, 4-amino-6-(((1s)-1-(3-chloro-6-phenylimidazo(1,2-b)pyridazin-7-yl)ethyl)amino)-
7. 5-pyrimidinecarbonitrile, 4-amino-6-[[(1s)-1-(3-chloro-6-phenylimidazo[1,2-b]pyridazin-7-yl)ethyl]amino]-
8. Amdizalisib [who-dd]
9. Amdizalisib [usan]
10. Unii-f3ymy7783p
11. Hmpl-689
12. Chembl4438249
13. Schembl17633481
14. Gtpl11699
15. Us10208066, Compound 4
16. Bdbm350391
17. Zinc584641354
18. Compound 4 [wo2016045591a1]
19. Compound 28 [pmid: 30582813]
20. Hy-132807
21. Cs-0204054
22. (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile
23. 4-amino-6-(((1s)-1-(3-chloro-6-phenylimidazo(1,2-b)pyridazin-7-yl)ethyl)amino)-5-pyrimidinecarbonitrile
| Molecular Weight | 390.8 g/mol |
|---|---|
| Molecular Formula | C19H15ClN8 |
| XLogP3 | 3.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 118 |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 576 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Amdizalisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Amdizalisib, including repackagers and relabelers. The FDA regulates Amdizalisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Amdizalisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Amdizalisib supplier is an individual or a company that provides Amdizalisib active pharmaceutical ingredient (API) or Amdizalisib finished formulations upon request. The Amdizalisib suppliers may include Amdizalisib API manufacturers, exporters, distributors and traders.
Amdizalisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Amdizalisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Amdizalisib GMP manufacturer or Amdizalisib GMP API supplier for your needs.
A Amdizalisib CoA (Certificate of Analysis) is a formal document that attests to Amdizalisib's compliance with Amdizalisib specifications and serves as a tool for batch-level quality control.
Amdizalisib CoA mostly includes findings from lab analyses of a specific batch. For each Amdizalisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Amdizalisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Amdizalisib EP), Amdizalisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Amdizalisib USP).
LOOKING FOR A SUPPLIER?
